JMAC vs. CDIO, ERNA, PHXM, RDHL, TNXP, KA, OBSV, ATHE, SHPH, and WENA
Should you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Cardio Diagnostics (CDIO), Eterna Therapeutics (ERNA), PHAXIAM Therapeutics (PHXM), RedHill Biopharma (RDHL), Tonix Pharmaceuticals (TNXP), Kineta (KA), ObsEva (OBSV), Alterity Therapeutics (ATHE), Shuttle Pharmaceuticals (SHPH), and ANEW Medical (WENA). These companies are all part of the "pharmaceutical products" industry.
Cardio Diagnostics (NASDAQ:CDIO) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.
Maxpro Capital Acquisition has lower revenue, but higher earnings than Cardio Diagnostics.
Cardio Diagnostics has a beta of 4.95, meaning that its stock price is 395% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500.
Cardio Diagnostics currently has a consensus target price of $2.00, suggesting a potential upside of 325.71%. Given Maxpro Capital Acquisition's higher possible upside, analysts clearly believe Cardio Diagnostics is more favorable than Maxpro Capital Acquisition.
In the previous week, Cardio Diagnostics had 3 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 3 mentions for Cardio Diagnostics and 0 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.96 beat Cardio Diagnostics' score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.
8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 30.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Maxpro Capital Acquisition has a net margin of 0.00% compared to Maxpro Capital Acquisition's net margin of -34,911.87%. Cardio Diagnostics' return on equity of 0.00% beat Maxpro Capital Acquisition's return on equity.
Cardio Diagnostics received 3 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users.
Summary
Cardio Diagnostics beats Maxpro Capital Acquisition on 8 of the 12 factors compared between the two stocks.
Get Maxpro Capital Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maxpro Capital Acquisition Competitors List
Related Companies and Tools
Free JMAC Stock Alerts